P19-07. Development of a protective HIV/SIV vaccine based on a self-boosting cytomegalovirus vector by Ambagala, A et al.
BioMed  Central
Page 1 of 1
(page number not for citation purposes)
Retrovirology
Open Access Poster presentation
P19-07. Development of a protective HIV/SIV vaccine based on a 
self-boosting cytomegalovirus vector
A Ambagala*2, DO Willer1, J Chan1, A Marsh1, P Sandstrom2, R Pilon2, 
J Fournier3 and KS MacDonald1
Address: 1Mount. Sinai Hospital/University of Toronto, Toronto, Canada, 2National HIV and Retrovirology Laboratories, Health Canada, Ottawa, 
Canada and 3Health Products and Food Branch, Health Canada, Ottawa, Canada
* Corresponding author    
Background
Human cytomegalovirus (HCMV) is a ubiquitous herpes-
virus responsible for asymptomatic, dormant, lifelong
infection in healthy individuals. HCMV frequently reacti-
vates inducing a strong, mucosally-oriented immune
response. These features of HCMV provide advantages
over other viral vectors investigated to date as HIV vaccine
candidates. Therefore, we hypothesize that an HCMV-
based vaccine can elicit safe and protective HIV-specific
immunity in humans. Cytomegaloviruses are highly spe-
cies-specific viruses and generally restricted in their ability
to infect even closely related hosts. Therefore, to test our
hypothesis, we propose to use rhesus cytomegalovirus
(RhCMV), a non-human primate cytomegalovirus, as a
vaccine vector to induce protective immunity to simian
immunodeficiency virus (SIV) in cynomolgus macaques
(CM). RhCMV is considered the best animal model for
HCMV, and SIV pathogenesis in CM closely mimics HIV/
AIDS pathogenesis in humans.
Methods
Phase 1: To determine if CMV sero-positive CM can be re-
infected with RhCMV and to evaluate immunogenicity of
the vector. Phase 2: Construction of RhCMV expressing
codon-optimized SIV antigens gag, pol, env and Nef-Tat-
Rev fusion protein, and assess the levels and pattern of SIV
antigen expression and growth in vitro. Phase 3: Compare
the in vivo growth and immunogenicity of these vectors
and their ability to confer protection following a multi-
low dose mucosal challenge with pathogenic SIVmac239
in CM.
Results
Phase 1: To differentiate RhCMV from endogenous
cynomolgus CMV, a recombinant RhCMV expressing
green fluorescent protein (RhCMV-EGFP) has been con-
structed. Six CMV seropositive adult CM were subcutane-
ously inoculated with live RhCMV-EGFP and two animals
were inoculated with UV-inactivated RhCMV-EGFP. Four
CM serve as control animals. Currently we are in the proc-
ess of evaluation of clinical and immunological responses
to the vaccine vector (RhCMV) and to EGFP.
Conclusion
This RhCMV-based SIV vaccine study will address key
issues of the immunogenicity, protective efficacy and self
boosting-capacity of this herpesvirus vector.
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